艾塞那肽治疗对2型糖尿病患者缓解期的影响研究

目的:研究艾塞那肽治疗对2型糖尿病患者缓解期的影响。方法:选择2009年11月-2010年10月我院内分泌科收治的57例2型糖尿病患者为研究对象,按照病程、体重指数、空腹餐后C肽、血脂、原有治疗方案一一配对分成艾塞那肽组(n=31)与对照组(n=26)。共治疗3个月,每月随访1次,检测血糖、糖化血红蛋白(HbA1c)、C肽、胰岛素,治疗前与治疗3个月后行72h动态血糖监测、静脉葡萄糖耐量试验。结果:艾塞那肽治疗3个月,16.13%(n=5)的2型糖尿病患者出现缓解期,与对照组比较差异有统计学意义(P<0.05);与治疗前比较,艾塞那肽治疗3个月的空腹血糖、餐后血糖、HbA1c下降,高血糖及低血糖所占时间比下降,差异有统计学意义(P<0.05)。结论:艾塞那肽治疗可促进2型糖尿病患者出现缓解期。

Effects of Exenatide Treatment on Remission Period of Patients with Type 2 Diabetes

OBJECTIVE:To investigate the effects of exenatide treatment on the remission period of patients with type 2 diabetes.METHODS:57 patients with type 2 diabetes in endocrinology department of our hospital from Nov.2009 to Oct.2010 were included and divided into exenatide group (n=31) and control group (n=26) according to disease duration,body weight index,fasting postprandial C Peptide,blood lipid,previous treatment scheme.During follow-up,plasma glucose,HbA1c,serum insulin and C peptide were evaluated every month.Before treatment and after 3 month,72 h dynamic glucose monitoring (DGM) and intravenous glucose tolerance test (IVGTT) were performed.RESULTS:In type 2 diabetics with the treatment of exenatide,16.13% (n=5) of them achieved remission,there was statistical significance between exenatide group and control group (P<0.05).Compared with before treatment,fasting blood glucose,postprandial blood glucose,HbA1c and the rate of hyperglycemia and hypoglycemia during DGM were significantly lowered after 3 months of treatment,there was statistical significance (P<0.05).CONCLUSION:Exenatide therapy can promote remission of patients with type 2 diabetes.